The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / From AIDS to Zika: ‘What’s next?’ asked Dr. Anthony Fauci in keynote address at the 2017 ACR/ARHP Annual Meeting

From AIDS to Zika: ‘What’s next?’ asked Dr. Anthony Fauci in keynote address at the 2017 ACR/ARHP Annual Meeting

November 5, 2017 • By Keri Losavio

  • Tweet
  • Email
Print-Friendly Version / Save PDF

SAN DIEGO—The 2017 ACR/ARHP Annual Meeting kicked off on Nov. 4 with a rousing presentation by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID). A terrorist attack on U.S. soil, hurricane, cyberattack and pandemic were the four scenarios played out in late 2016, when NIAID conducted a tabletop exercise for the newly elected president’s incoming cabinet.

You Might Also Like
  • 2017 ACR/ARHP Annual Meeting Highlights
  • Heart of a Champion: The 2018 ACR/ARHP Annual Meeting Kicks Off with Dramatic Keynote
  • The ACR Early Career Investigators to Host Sessions at 2017 ACR/ARHP Annual Meeting
Explore This Issue
December 2017
Also By This Author
  • Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19

In this first year of Donald Trump’s presidency, three of these four potential disasters have already occurred: We’ve had a terrorist attack in Las Vegas. Hurricanes Harvey, Irma and Maria wreaked untold damage in Texas, Florida and Puerto Rico. And the extent of Russia’s cyberattacks and interference in the election is still being uncovered. “That leaves pandemic,” said Dr. Fauci.

Anthony S. Fauci, MD (NIAID)

Anthony S. Fauci, MD (NIAID)

In Dr. Fauci’s keynote address, Emerging & Reemerging Infectious Diseases: From AIDS to Zika, he recapped what the world has learned in the past 30-odd years from our experience with infectious diseases, such as HIV/AIDS, influenza, SARS, West Nile, Ebola and Zika.

Dr. Fauci was appointed director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose and treat established infectious diseases. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2017 is approximately $4.9 billion.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Fauci has advised five presidents and the U.S. Department of Health and Human Services on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief, a program that has saved millions of lives throughout the developing world.

AIDS/HIV
The AIDS epidemic was the topic of Dr. Fauci’s first appearance before Congress following his appointment to NIAID by President Ronald Reagan. He said, “… because we do not know the cause of this syndrome, any assumption that the syndrome will remain restricted to a particular segment of our society is truly an assumption without scientific basis.”

As of 2016, globally, 76.1 million people have been infected with HIV, and 35 million people have died from AIDS-related illnesses—1 million died in 2016 alone. But that’s only part of the picture. 36.7 million people are living with HIV. That’s right, living with the disease. Funding for research made the difference.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In fact, following diagnosis in today’s world, Dr. Fauci can tell patients that they have a life expectancy of 53 years. When Dr. Fauci was first reporting on AIDS/HIV to Congress, the cause was unknown, patients were diagnosed late into their illness and they had a life expectancy of 8 to 15 months. Today, if you assume a patient is diagnosed in their 20s, they have a near-normal life expectancy. That progress led Dr. Fauci to state an important lesson he’s learned in his career: “When we put resources into a disease, we can get results.”

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports Tagged With: 2017 ACR/ARHP Annual MeetingIssue: December 2017

You Might Also Like:
  • 2017 ACR/ARHP Annual Meeting Highlights
  • Heart of a Champion: The 2018 ACR/ARHP Annual Meeting Kicks Off with Dramatic Keynote
  • The ACR Early Career Investigators to Host Sessions at 2017 ACR/ARHP Annual Meeting
  • 2018 ACR/ARHP Annual Meeting Courses, Opening Lecture & Keynote

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.